Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group

Simple item page
dc.contributor.authorCleeland, C. S.
dc.contributor.authorPortenoy, R. K.
dc.contributor.authorRué i Monné, Montserrat
dc.contributor.authorMendoza, T. R.
dc.contributor.authorWeller, E.
dc.contributor.authorPayne, R.
dc.contributor.authorKirshner, J.
dc.contributor.authorAtkins, J. N.
dc.contributor.authorJohnson, P. A.
dc.contributor.authorMarcus, A.
dc.date.accessioned2016-05-24T07:39:08Z
dc.date.embargoEndDate2025-01-01
dc.date.issued2005
dc.description.abstractBackground: Cancer pain is highly prevalent and commonly undertreated. This study was designed to determine whether dissemination of a clinical protocol for pain management would improve outcomes in community oncology practices. Patients and methods: A pain management protocol was developed based on accepted guidelines. After baseline assessment, oncology practices were randomly assigned to ‘analgesic protocol’ (AP) sites, where oncologists implemented the guidelines in a group of lung or prostate cancer patients, or to ‘physician discretion’ (PD) sites, where customary treatment was continued. Patients treated on protocol and a comparison group of patients with pain due to breast cancer or myeloma were monitored for change in pain using the Brief Pain Inventory, and for change in other symptoms or mood. Results: The protocol terminated early because of poor accrual. We compared groups using proportions of patients who had no or mild pain at follow-up. Although measures of protocol adherence did not suggest the occurrence of major practice change, the proportion of lung or prostate cancer patients with no or mild pain increased significantly from baseline for those treated at AP sites compared with those treated at PD sites. There was no significant difference between the breast and myeloma patients treated at AP sites versus those treated at PD sites. Conclusion: A protocol for cancer pain management can improve pain control. Diffusion of these benefits to other patients was not confirmed. Given the small sample size, these findings require confirmation in a larger trial.ca_ES
dc.identifier.doihttps://doi.org/10.1093/annonc/mdi191
dc.identifier.idgrec009158
dc.identifier.issn0923-7534
dc.identifier.urihttp://hdl.handle.net/10459.1/57086
dc.language.isoengca_ES
dc.publisherOxford University Pressca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1093/annonc/mdi191ca_ES
dc.relation.ispartofAnnals of Oncology, 2005, vol. 16, núm. 6, p. 972-980ca_ES
dc.rights(c) European Society for Medical Oncology, 2005ca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccessca_ES
dc.subjectBrief Pain Inventoryca_ES
dc.subjectCancer painca_ES
dc.subjectManagement guidelinesca_ES
dc.subjectRandomized clinical trialca_ES
dc.titleDoes an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Groupca_ES
dc.typearticleca_ES
dc.type.versionpublishedVersionca_ES
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Articles publicats (Ciències Mèdiques Bàsiques)